Find Clinical Trials
Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. A 28-weeks, randomised, double-blind, parallel-group, placebo controlled, international multicentre exploratory pilot study
Servier Protocol Code:
CL2-78989-009
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2012-002677-53
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Coronary Artery Disease
- GEVOKIZUMAB
- S078989
Other study id numbers
Other identification numbers the study may be known by.
- CL2-78989-009